Skin testing in genitourinary carcinoma: 2-year followup.
Compound 2,4 dinitrofluorobenzene was used to sensitize 115 patients with genitourinary cancer to test their ability to be immunized with a newly encountered antigen. In general, patients in whom a cutaneous hypersensitivity response did not develop were more likely to have advanced stage tumors than patients whose immunocompetence was intact. A 2 to 3-year followup showed that patients with impaired cell-mediated immunity were more likely to undergo disease advancement than patients of similar stage whose immunity was normal. Unfortunately, these results cannot be extrapolated for application to a given patient.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000941:Antigens; D002648:Child; D002675:Child, Preschool; D004139:Dinitrofluorobenzene / Q000276:immunology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007111:Immunity, Cellular; D007114:Immunization; D007680:Kidney Neoplasms / Q000276:immunology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000276:immunology; D012882:Skin Tests; D013736:Testicular Neoplasms / Q000276:immunology; D001749:Urinary Bladder Neoplasms / Q000276:immunology; D014565:Urogenital Neoplasms / Q000276:immunology*
D000941:Antigens; D004139:Dinitrofluorobenzene